Homocysteine inhibits the viability and migration ability of human umbilical vein endothelial cells by downregulating the expression of vascular endothelial growth factor

Yu,Jian; Zhang,Ling‑Ling; Wu,Xiao‑Peng; Zhao,Rui; Meng,Zhi‑Xin; Wang,Kun; Wang,Bin; Wang,Hui; Shi,Zuo‑Lei; Li,Guang‑Xin

doi:10.3892/etm.2019.8043

Homocysteine inhibits the viability and migration ability of human umbilical vein endothelial cells by downregulating the expression of vascular endothelial growth factor

Authors:
- Jian Yu
- Ling‑Ling Zhang
- Xiao‑Peng Wu
- Rui Zhao
- Zhi‑Xin Meng
- Kun Wang
- Bin Wang
- Hui Wang
- Zuo‑Lei Shi
- Guang‑Xin Li
View Affiliations

Affiliations: Department of Vascular Surgery, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P.R. China, Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: September 25, 2019 https://doi.org/10.3892/etm.2019.8043
Pages: 3913-3919
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to explore the effect of homocysteine (Hcy) on the viability and migration ability of human umbilical vein endothelial cells (HUVECs), as well as to examine the underlying mechanism. The association between the expression level of Hcy and lower extremity deep vein thrombosis (DVT) was detected in clinical samples collected from patients. In addition, the effect of Hcy on the viability and migration ability of HUVECs was detected by cell counting kit‑8 and Transwell assays, respectively, while vascular endothelial growth factor (VEGF) expression was measured in order to verify the effect of Hcy on VEGF. The results indicated that the serum Hcy levels in DVT patients were significantly increased. In vitro experiments also confirmed that Hcy was able to significantly inhibit the viability and migration ability of HUVECs, and downregulate the expression of VEGF in these cells. Furthermore, the inhibitory effect of Hcy on HUVEC viability and migration ability was achieved by downregulating the expression of VEGF using small interfering RNA transfection. In conclusion, Hcy inhibited the viability and migration ability of HUVECs by downregulating the expression of VEGF. This may underlie the high incidence of DVT in patients with hyperhomocysteinemia.

View Figures

View References

1	Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV and Fowkes FG: Incidence and risk factors for venous reflux in the general population: Edinburgh vein study. Eur J Vasc Endovasc Surg. 48:208–214. 2014. View Article : Google Scholar : PubMed/NCBI
2	White RH: The epidemiology of venous thromboembolism. Circulation. 107 (Suppl 1):I4–I18. 2003. View Article : Google Scholar : PubMed/NCBI
3	Hsu TS, Hsu LA, Chang CJ, Sun CF, Ko YL, Kuo CT, Chiang CW and Lee YS: Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study. Thromb Res. 102:387–395. 2001. View Article : Google Scholar : PubMed/NCBI
4	Boers GH: Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost. 78:520–522. 1997. View Article : Google Scholar : PubMed/NCBI
5	Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L and Girolami A: Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost. 76:883–886. 1996. View Article : Google Scholar : PubMed/NCBI
6	Ospina-Romero M, Cannegieter SC, den Heijer M, Doggen CJM, Rosendaal FR and Lijfering WM: Hyperhomocysteinemia and risk of first venous thrombosis: The influence of (Unmeasured) confounding factors. Am J Epidemiol. 187:1392–1400. 2018. View Article : Google Scholar : PubMed/NCBI
7	De Stefano V, Casorelli I, Rossi E, Zappacosta B and Leone G: Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost. 26:305–311. 2000. View Article : Google Scholar : PubMed/NCBI
8	Makris M: Hyperhomocysteinemia and thrombosis. Clin Lab Haematol. 22:133–143. 2000. View Article : Google Scholar : PubMed/NCBI
9	Ebbesen LS: Hyperhomocysteinemia, thrombosis and vascular biology. Cell Mol Biol (Noisy-le-grand). 50:917–930. 2004.PubMed/NCBI
10	Fridman O: Hyperhomocysteinemia: Atherothrombosis and neurotoxicity. Acta Physiol Pharmacol Ther Latinoam. 49:21–30. 1999.(In Spanish). PubMed/NCBI
11	Makin AJ, Chung NA, Silverman SH and Lip GY: Alterations of thrombogenesis, endothelial damage and oxidative stress with reperfusion during femoral artery bypass surgery for peripheral vascular disease. Pathophysiol Haemost Thromb. 32:158–164. 2002. View Article : Google Scholar : PubMed/NCBI
12	Sametz W, Prasthofer S, Wintersteiger R and Juan H: Vascular effects of isoprostanes after endothelial damage. Prostaglandins Leukot Essent Fatty Acids. 61:369–372. 1999. View Article : Google Scholar : PubMed/NCBI
13	Spaet TH and Gaynor E: Vascular endothelial damage and thrombosis. Adv Cardiol. 4:47–66. 1970. View Article : Google Scholar : PubMed/NCBI
14	Stubbs MJ, Mouyis M and Thomas M: Deep vein thrombosis. BMJ. 360:k3512018. View Article : Google Scholar : PubMed/NCBI
15	Theodorou K and Boon RA: Endothelial cell metabolism in atherosclerosis. Front Cell Dev Biol. 6:822018. View Article : Google Scholar : PubMed/NCBI
16	Wen HC, Kao C, Hsu RC, Huo YN, Ting PC, Chen LC, Hsu SP, Juan SH and Lee WS: Thy-1-induced migration inhibition in vascular endothelial cells through reducing the RhoA activity. PLoS One. 8:e615062013. View Article : Google Scholar : PubMed/NCBI
17	Coultas L, Chawengsaksophak K and Rossant J: Endothelial cells and VEGF in vascular development. Nature. 438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
18	Rosendaal FR: Venous thrombosis: A multicausal disease. Lancet. 353:1167–1173. 1999. View Article : Google Scholar : PubMed/NCBI
19	Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 81:165–176. 1999. View Article : Google Scholar : PubMed/NCBI
20	Yang RX, Huang SY, Yan FF, Lu XT, Xing YF, Liu Y, Liu YF and Zhao YX: Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia. Acta Pharmacol Sin. 31:1395–1400. 2010. View Article : Google Scholar : PubMed/NCBI
21	Cattaneo M: Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost. 32:716–723. 2006. View Article : Google Scholar : PubMed/NCBI
22	den Heijer M and Keijzer MB: Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med. 39:710–713. 2001.PubMed/NCBI
23	de Groot K, Goldberg C, Bahlmann FH, Woywodt A, Haller H, Fliser D and Haubitz M: Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 56:3847–3853. 2007. View Article : Google Scholar : PubMed/NCBI
24	Pinedo HM: The role of VEGF in oncology: Effects on hemostasis and thrombosis. Pathophysiol Haemost Thromb. 33 (Suppl 1):S11–S12. 2003. View Article : Google Scholar
25	Swanson N, Hogrefe K, Javed Q, Malik N and Gershlick AH: Vascular endothelial growth factor (VEGF)-eluting stents: In vivo effects on thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol. 15:688–692. 2003.PubMed/NCBI
26	Abdel-Rahman O and ElHalawani H: Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents. Crit Rev Oncol Hematol. 102:89–100. 2016. View Article : Google Scholar : PubMed/NCBI
27	Girardi F, Franceschi E and Brandes AA: Cardiovascular safety of VEGF-targeting therapies: Current evidence and handling strategies. Oncologist. 15:683–694. 2010. View Article : Google Scholar : PubMed/NCBI
28	Koransky ML, Robbins RC and Blau HM: VEGF gene delivery for treatment of ischemic cardiovascular disease. Trends Cardiovasc Med. 12:108–114. 2002. View Article : Google Scholar : PubMed/NCBI
29	Schaper W and Buschmann I: VEGF and therapeutic opportunities in cardiovascular diseases. Curr Opin Biotechnol. 10:541–543. 1999. View Article : Google Scholar : PubMed/NCBI